REDUCTION OF COMPLICATIONS AND ASSOCIATED COSTS FOR TYPE 2 DIABETIC PATIENTS USING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN THE UK

被引：0
|
作者：
Roze, S. [1 ]
Duteil, E. [2 ]
Hallas, N. [3 ]
de Portu, S. [4 ]
机构：
[1] HEVA HEOR Sarl, Lyon, France
[2] HEVA HEOR, Lyon, France
[3] Medtronic, Watford, England
[4] Medtron Int Sarl, Tolochenaz, Switzerland
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMD90
引用
收藏
页码：A360 / A360
页数：1
相关论文
共 50 条
  • [1] IMPACT OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION ON DIABETES RELATED COMPLICATIONS AND ASSOCIATED COSTS IN TYPE 2 DIABETES PATIENTS IN FINLAND
    Roze, S.
    Delbaere, A.
    de Portu, S.
    Bjornstrom, K.
    Honkasalo, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A27 - A28
  • [2] IMPACT OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION ON DIABETES RELATED COMPLICATIONS AND ASSOCIATED COSTS IN TYPE 2 DIABETES PATIENTS IN SWEDEN
    Roze, S.
    Duteil, E.
    Delbaere, A.
    De Portu, S.
    Brandt, A. S.
    Hellman, J.
    Frid, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A19 - A19
  • [3] Insulin Requirement Profiles and Characteristics of Type 2 Diabetic Patients With Continuous Subcutaneous Insulin Infusion Therapy
    Zhang, Xiuzhen
    Yan, Jinhua
    Xu, Haixia
    Xu, Wen
    Yao, Bin
    Zhu, Yanhua
    Zhang, Guochao
    Weng, Jianping
    DIABETES, 2013, 62 : A248 - A249
  • [4] Continuous glucose monitoring in type 1 diabetic patients with continuous subcutaneous insulin infusion
    Alves, Marta
    Neves, Celestino
    Varela, Ana
    Arteiro, Cristina
    Pereira, Luis M.
    Carvaiho, Davide
    Medina, Jose L.
    DIABETES, 2008, 57 : A547 - A547
  • [5] REDUCTION OF SEVERE HYPOGLYCEMIC EVENTS IN TYPE-I (INSULIN DEPENDENT) DIABETIC-PATIENTS USING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION
    EICHNER, HL
    SELAM, JL
    HOLLEMAN, CB
    WORCESTER, BR
    TURNER, DS
    CHARLES, MA
    DIABETES RESEARCH CLINICAL AND EXPERIMENTAL, 1988, 8 (04): : 189 - 193
  • [6] Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients
    Bruttomesso, D
    Fongher, C
    Silvestri, B
    Barberio, S
    Marescotti, MC
    Iori, E
    Valerio, A
    Crazzolara, D
    Pianta, A
    Tiengo, A
    Del Prato, S
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2001, 51 (02) : 97 - 105
  • [7] Related Factors of Insulin Dose Setting in Type 2 Diabetic Patients Treated with Continuous Subcutaneous Insulin Infusion
    Xu, Wen
    Zhang, Xiuzhen
    Luo, Sihui
    Zhu, Yanhua
    Yan, Jinhua
    Yao, Bin
    Weng, Jianping
    DIABETES, 2015, 64 : A258 - A258
  • [8] Continuous subcutaneous insulin infusion (CSII) in patients with Type 2 diabetes
    Lenhard, MJ
    Maser, RE
    DIABETES, 2001, 50 : A440 - A441
  • [9] Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs
    Guerci, B
    Floriot, M
    Böhme, P
    Durain, D
    Benichou, M
    Jellimann, S
    Drouin, P
    DIABETES CARE, 2003, 26 (03) : 582 - 589
  • [10] DIABETIC-KETOACIDOSIS ASSOCIATED WITH OUTPATIENT TREATMENT USING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION
    BOULTON, AJM
    DRURY, J
    KNIGHT, G
    WARD, JD
    POSTGRADUATE MEDICAL JOURNAL, 1983, 59 (693) : 438 - 439
12345